Scientific Program

The Group’s scientific program includes all phases of clinical research (phases 1 to 4). It also covers all types and subtypes of breast cancer: Hormone-receptor-positive – estrogen or progesterone (HR +); HER2 protein overexpression (HER2 +); Triple-negative, which does not involve hormone receptors nor those of the HER2 protein (HR- / HER2-); Genetic mutation (somatic / spontaneous or hereditary / transmitted), as well as all stages of the disease or extent of cancer, from in situ and early stages to metastatic cancer.

Cancer SubtypeTime of treatmentTreatment Types
HR+/HER2-NeoadjuvantChemotherapy
HR-/HER2+AdjuvantHormonal therapy
HR-/HER2- (mutated or not)Post-NeoadjuvantImmunotherapy
HR+/HER2+Prevention
Genetic Mutations Radiation therapy
Supportive therapy
Surgery
Targeted therapy

Clinical Trials Performed Within the Group

The consortium is presently involved in over 40 or so clinical trials and is considering new ones regularly. Please refer to the table below which only lists trials that are currently in preparation or in recruitment at the Group’s hospitals.

How to use this table:
– Use the arrows to sort the columns in alphabetical order (in particular to sort the studies by status)
– Use the Search field with any keyword (hospital centre, cancer subtype etc.)

Cancer SubtypeStudy NameSponsorParticipating HospitalsStatus
HR+/HER2-SERENA-6
A phase 3, double-bliind, randomized study to assess the efficacy and safety of switching to AZD9833 (an oral SERD) + CDK4/6 inhibitors (palbociclib or abemaciclib) vs continuing aromatase inhibitor + CDK4/6 inhibitors in patients with acquired ESR1 mutation without radiological progression during 1L treatment with AI + CDK4/6i for ER+/HER2- mBC-ctDNA guided early switch study
AstraZenecaCIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL

CHU DE QUEBEC – UNIVERSITE LAVAL

CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT
In recruitment
HR+/HER2-SERENA-4
A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) Plus Palbociclib Versus Anastrozole Plus Palbociclib for the Treatment of Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
AstraZenecaCIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITALIn recruitment
HR+/HER2-CAPItello-292
A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) Plus Palbociclib Versus Anastrozole Plus Palbociclib for the Treatment of Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
AstraZenecaCIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL

CIUSSS SAGUENAY-LAC-ST-JEAN / HÔPITAL DE CHICOUTIMI
In recruitment
HER2+HER2CLIMB-05
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer
SeagenCIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL

CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

CIUSSS DU SAGUENAY-LAC-SAINT-JEAN / HÔPITAL DE CHICOUTIMI
In recruitment
HER2+MO43110
A Phase IIIB, Multinational, Multicenter, Randomized, Open-Label Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer
Hoffmann-LaRoche CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL / HOPITAL GENERAL JUIF

CHU DE QUEBEC – UNIVERSITE LAVAL
In recruitment
HR- & HER2- (triple negative)TROPION-Breast-02
A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION Breast02)
AstraZenecaCHU DE QUEBEC - UNIVERSITÉ LAVAL

CENTRE UNIVERSITAIRE DE SANTÉ MCGILL (CUSM)

CISSS MONTÉRÉGIE CENTRE / HÔPITAL CHARLES-LEMOYNE
In recruitment
HR- & HER2- (triple negative)TROPION-Breast-03
A Study of Dato-DXd With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response at the Time of Surgery Following Neoadjuvant Therapy
AstraZenecaCIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL / HOPITAL GENERAL JUIF

CHU DE QUEBEC - UNIVERSITÉ LAVAL

CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

CENTRE UNIVERSITAIRE DE SANTÉ MCGILL (CUSM)
In recruitment
HR+ & HER2- CELC-G-301
A phase 3, open-label, randomized, two-part study comparing gedatolisib in combination with palbociclib and fulvestrant to standard-of-care therapies in patients with hr-positive, her2-negative advanced breast cancer previously treated with a cdk4/6 inhibitor in combination with non-steroidal aromatase inhibitor therapy (viktoria-1)
CelcuityCENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT

CIUSSS SAGUENAY-LAC-ST-JEAN / HÔPITAL DE CHICOUTIMI
In recruitment
HR+ & HER2- CAMBRIA-1
A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer
Astra ZenecaCENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

CENTRE UNIVERSITAIRE DE SANTÉ MCGILL (CUSM)

CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT
In preparation
HR- & HER2- (triple négatif)TROPION-Breast-04
A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Untreated Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer
Astra ZenecaCIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL

CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

CENTRE UNIVERSITAIRE DE SANTÉ MCGILL (CUSM)

CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT

CIUSSS DE L'ESTRIE - CHUS

CISSS DE CHAUDIÈRE-APPALACHES

In recruitment
HR+ & HER2-INAVO-121
A Phase III, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Versus Alpelisib Plus Fulvestrant in Patients With Hormone Receptor-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Who Progressed During or After CDK4/6 Inhibitor and Endocrine Combination Therapy
Hoffmann-LaRocheCIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL / HOPITAL GENERAL JUIF

CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)


CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL / HOPITAL MAISONNEUVE-ROSEMONT

CIUSSS DU NORD-DE-L’ÎLE-DE-MONTRÉAL / HÔPITAL DU SACRÉ-CŒUR-DE-MONTRÉAL
In recruitment
HR+ or HR- & HER2+INAVO-122
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo As Maintenance Therapy After First Line Induction Therapy in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
Hoffmann-LaRoche CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL / HOPITAL GENERAL JUIF

CHU DE QUEBEC - UNIVERSITÉ LAVAL

CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

CIUSSS DU NORD-DE-L’ÎLE-DE-MONTRÉAL / HÔPITAL DU SACRÉ-CŒUR-DE-MONTRÉAL
In recruitment
HR+ & HER2-pionERA Breast Cancer
A Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib), in participants with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer who have developed resistance to adjuvant endocrine therapy.
Hoffmann-LaRoche CHU DE QUEBEC - UNIVERSITÉ LAVAL

CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

CENTRE UNIVERSITAIRE DE SANTÉ MCGILL (CUSM)

CIUSSS SAGUENAY-LAC-ST-JEAN / HÔPITAL DE CHICOUTIMI
In recruitment
HR+ & HER2-Adjuvant WIDER
A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer
NovartisCHU DE QUEBEC - UNIVERSITÉ LAVAL

CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

CENTRE UNIVERSITAIRE DE SANTÉ MCGILL (CUSM)
In preparation
Available soonC4391025

Summary available soon
PfizerCENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

CENTRE UNIVERSITAIRE DE SANTÉ MCGILL (CUSM)
In preparation
HR+ & HER2-CAMBRIA-2
A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
Astra ZenecaCHU DE QUEBEC - UNIVERSITÉ LAVAL

CENTRE UNIVERSITAIRE DE SANTÉ MCGILL (CUSM)

CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT

CIUSSS SAGUENAY-LAC-ST-JEAN / HÔPITAL DE CHICOUTIMI

CISSS DE CHAUDIÈRE-APPALACHES
In recruitment
HR+ & HER2 lowDYNASTY-Breast-02
A Phase 3, Randomized, Multi-center, Open-Label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-Low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy (ET)
DualityBioCIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL / HOPITAL GENERAL JUIF

CENTRE UNIVERSITAIRE DE SANTÉ MCGILL
(CUSM)

CIUSSS DE L'ESTRIE – CHUS

CIUSSS DE L'OUEST-DE-L'ILE-DE-MONTREAL/ ST. MARY'S HOSPITAL
In preparation
HR+ or HR- & HER2+ or HER2-EXActDNA-003 (Exact 2023-05) NSABP B-64Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated With Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual DiseaseExact Sciences Corporation & NSABPCIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL / HOPITAL GENERAL JUIF

CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

CHU DE QUEBEC - UNIVERSITÉ LAVAL

CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL / HOPITAL MAISONNEUVE-ROSEMONT
In preparation
HR+ & HER2-MK-2870-010
An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer
MerckCIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL / HOPITAL GENERAL JUIF


CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL / HOPITAL MAISONNEUVE-ROSEMONT
In preparation
HR- & HER2-MK-2870-012
A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice (TPC) in Participants With Triple-Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) at Surgery
MerckCIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL / HOPITAL GENERAL JUIF

CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL / HOPITAL MAISONNEUVE-ROSEMONT

CISSS MONTÉRÉGIE CENTRE / HÔPITAL CHARLES-LEMOYNE
In preparation
HR+ & HER2-OPERA-01
A Phase 3 Randomized, Open-Label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK 4/6 Inhibitor Therapy (OPERA-01)
Olema PharmaceuticalsCENTRE UNIVERSITAIRE DE SANTÉ MCGILL (CUSM)In preparation
HR- & HER2-TROPION-BREAST-05
A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
Astra ZenecaCHU DE QUEBEC - UNIVERSITÉ LAVAL

CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

CENTRE UNIVERSITAIRE DE SANTÉ MCGILL (CUSM)

CISSS MONTÉRÉGIE CENTRE / HÔPITAL CHARLES-LEMOYNE
In preparation
Cancer SubtypeStudy NameSponsorParticipating HospitalsStatus
HR+/HER2-SERENA-6
A phase 3, double-bliind, randomized study to assess the efficacy and safety of switching to AZD9833 (an oral SERD) + CDK4/6 inhibitors (palbociclib or abemaciclib) vs continuing aromatase inhibitor + CDK4/6 inhibitors in patients with acquired ESR1 mutation without radiological progression during 1L treatment with AI + CDK4/6i for ER+/HER2- mBC-ctDNA guided early switch study
AstraZenecaCIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL

CHU DE QUEBEC – UNIVERSITE LAVAL

CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT
In recruitment
HR+/HER2-SERENA-4
A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) Plus Palbociclib Versus Anastrozole Plus Palbociclib for the Treatment of Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
AstraZenecaCIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITALIn recruitment
HR+/HER2-CAPItello-292
A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) Plus Palbociclib Versus Anastrozole Plus Palbociclib for the Treatment of Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
AstraZenecaCIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL

CIUSSS SAGUENAY-LAC-ST-JEAN / HÔPITAL DE CHICOUTIMI
In recruitment
HER2+HER2CLIMB-05
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer
SeagenCIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL

CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

CIUSSS DU SAGUENAY-LAC-SAINT-JEAN / HÔPITAL DE CHICOUTIMI
In recruitment
HER2+MO43110
A Phase IIIB, Multinational, Multicenter, Randomized, Open-Label Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer
Hoffmann-LaRoche CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL / HOPITAL GENERAL JUIF

CHU DE QUEBEC – UNIVERSITE LAVAL
In recruitment
HR- & HER2- (triple negative)TROPION-Breast-02
A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION Breast02)
AstraZenecaCHU DE QUEBEC - UNIVERSITÉ LAVAL

CENTRE UNIVERSITAIRE DE SANTÉ MCGILL (CUSM)

CISSS MONTÉRÉGIE CENTRE / HÔPITAL CHARLES-LEMOYNE
In recruitment
HR- & HER2- (triple negative)TROPION-Breast-03
A Study of Dato-DXd With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response at the Time of Surgery Following Neoadjuvant Therapy
AstraZenecaCIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL / HOPITAL GENERAL JUIF

CHU DE QUEBEC - UNIVERSITÉ LAVAL

CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

CENTRE UNIVERSITAIRE DE SANTÉ MCGILL (CUSM)
In recruitment
HR+ & HER2- CELC-G-301
A phase 3, open-label, randomized, two-part study comparing gedatolisib in combination with palbociclib and fulvestrant to standard-of-care therapies in patients with hr-positive, her2-negative advanced breast cancer previously treated with a cdk4/6 inhibitor in combination with non-steroidal aromatase inhibitor therapy (viktoria-1)
CelcuityCENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT

CIUSSS SAGUENAY-LAC-ST-JEAN / HÔPITAL DE CHICOUTIMI
In recruitment
HR+ & HER2- CAMBRIA-1
A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer
Astra ZenecaCENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

CENTRE UNIVERSITAIRE DE SANTÉ MCGILL (CUSM)

CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT
In preparation
HR- & HER2- (triple négatif)TROPION-Breast-04
A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Untreated Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer
Astra ZenecaCIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL

CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

CENTRE UNIVERSITAIRE DE SANTÉ MCGILL (CUSM)

CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT

CIUSSS DE L'ESTRIE - CHUS

CISSS DE CHAUDIÈRE-APPALACHES

In recruitment
HR+ & HER2-INAVO-121
A Phase III, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Versus Alpelisib Plus Fulvestrant in Patients With Hormone Receptor-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Who Progressed During or After CDK4/6 Inhibitor and Endocrine Combination Therapy
Hoffmann-LaRocheCIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL / HOPITAL GENERAL JUIF

CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)


CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL / HOPITAL MAISONNEUVE-ROSEMONT

CIUSSS DU NORD-DE-L’ÎLE-DE-MONTRÉAL / HÔPITAL DU SACRÉ-CŒUR-DE-MONTRÉAL
In recruitment
HR+ or HR- & HER2+INAVO-122
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo As Maintenance Therapy After First Line Induction Therapy in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
Hoffmann-LaRoche CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL / HOPITAL GENERAL JUIF

CHU DE QUEBEC - UNIVERSITÉ LAVAL

CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

CIUSSS DU NORD-DE-L’ÎLE-DE-MONTRÉAL / HÔPITAL DU SACRÉ-CŒUR-DE-MONTRÉAL
In recruitment
HR+ & HER2-pionERA Breast Cancer
A Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib), in participants with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer who have developed resistance to adjuvant endocrine therapy.
Hoffmann-LaRoche CHU DE QUEBEC - UNIVERSITÉ LAVAL

CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

CENTRE UNIVERSITAIRE DE SANTÉ MCGILL (CUSM)

CIUSSS SAGUENAY-LAC-ST-JEAN / HÔPITAL DE CHICOUTIMI
In recruitment
HR+ & HER2-Adjuvant WIDER
A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer
NovartisCHU DE QUEBEC - UNIVERSITÉ LAVAL

CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

CENTRE UNIVERSITAIRE DE SANTÉ MCGILL (CUSM)
In preparation
Available soonC4391025

Summary available soon
PfizerCENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

CENTRE UNIVERSITAIRE DE SANTÉ MCGILL (CUSM)
In preparation
HR+ & HER2-CAMBRIA-2
A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
Astra ZenecaCHU DE QUEBEC - UNIVERSITÉ LAVAL

CENTRE UNIVERSITAIRE DE SANTÉ MCGILL (CUSM)

CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT

CIUSSS SAGUENAY-LAC-ST-JEAN / HÔPITAL DE CHICOUTIMI

CISSS DE CHAUDIÈRE-APPALACHES
In recruitment
HR+ & HER2 lowDYNASTY-Breast-02
A Phase 3, Randomized, Multi-center, Open-Label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-Low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy (ET)
DualityBioCIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL / HOPITAL GENERAL JUIF

CENTRE UNIVERSITAIRE DE SANTÉ MCGILL
(CUSM)

CIUSSS DE L'ESTRIE – CHUS

CIUSSS DE L'OUEST-DE-L'ILE-DE-MONTREAL/ ST. MARY'S HOSPITAL
In preparation
HR+ or HR- & HER2+ or HER2-EXActDNA-003 (Exact 2023-05) NSABP B-64Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated With Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual DiseaseExact Sciences Corporation & NSABPCIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL / HOPITAL GENERAL JUIF

CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

CHU DE QUEBEC - UNIVERSITÉ LAVAL

CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL / HOPITAL MAISONNEUVE-ROSEMONT
In preparation
HR+ & HER2-MK-2870-010
An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer
MerckCIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL / HOPITAL GENERAL JUIF


CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL / HOPITAL MAISONNEUVE-ROSEMONT
In preparation
HR- & HER2-MK-2870-012
A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice (TPC) in Participants With Triple-Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) at Surgery
MerckCIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL / HOPITAL GENERAL JUIF

CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL / HOPITAL MAISONNEUVE-ROSEMONT

CISSS MONTÉRÉGIE CENTRE / HÔPITAL CHARLES-LEMOYNE
In preparation
HR+ & HER2-OPERA-01
A Phase 3 Randomized, Open-Label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK 4/6 Inhibitor Therapy (OPERA-01)
Olema PharmaceuticalsCENTRE UNIVERSITAIRE DE SANTÉ MCGILL (CUSM)In preparation
HR- & HER2-TROPION-BREAST-05
A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
Astra ZenecaCHU DE QUEBEC - UNIVERSITÉ LAVAL

CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM)

CENTRE UNIVERSITAIRE DE SANTÉ MCGILL (CUSM)

CISSS MONTÉRÉGIE CENTRE / HÔPITAL CHARLES-LEMOYNE
In preparation